Bronnen:
- Schadendorf D, Hauschild A, Santinami M, et al. Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2019 Mar 27. pii: S1470-2045(18)30940-9. [Epub ahead of print]